PCIA
MRNA icon

Prime Capital Investment Advisors’s Moderna MRNA Stock Holding History

Prime Capital Investment Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$349K Buy
4,985
+346
+7% +$17.9K ﹤0.01% 810
2026
Q1 		$236K Buy
+4,639
New +$216K ﹤0.01% 925
2025
Q1 		– Sell
-5,188
Closed -$216K – 1093
2024
Q4 		$216K Buy
+5,188
New +$248K ﹤0.01% 836
2024
Q3 		– Sell
-3,613
Closed -$429K – 953
2024
Q2 		$429K Sell
3,613
-906
-20% -$115K 0.01% 618
2024
Q1 		$482K Sell
4,519
-7,733
-63% -$779K 0.01% 626
2023
Q4 		$1.22M Sell
12,252
-5,021
-29% -$422K 0.02% 400
2023
Q3 		$1.78M Sell
17,273
-9,273
-35% -$1.03M 0.04% 263
2023
Q2 		$3.23M Buy
26,546
+12,487
+89% +$1.67M 0.06% 213
2023
Q1 		$2.16M Sell
14,059
-9,116
-39% -$1.5M 0.09% 159
2022
Q4 		$4.16M Buy
23,175
+15,897
+218% +$2.6M 0.16% 116
2022
Q3 		$861K Sell
7,278
-15,009
-67% -$2.28M 0.05% 185
2022
Q2 		$3.18M Buy
22,287
+17,556
+371% +$2.51M 0.19% 94
2022
Q1 		$1.2M Hold
4,731
– – 0.07% 162
2021
Q4 		$1.2M Sell
4,731
-8,042
-63% -$2.35M 0.06% 166
2021
Q3 		$4.92M Buy
+12,773
New +$4.71M 0.31% 62
2021
Q2 		– Sell
-1,135
Closed -$149K – 483
2021
Q1 		$149K Sell
1,135
-117
-9% -$17K 0.01% 264
2020
Q4 		$131K Sell
1,252
-8,773
-88% -$888K 0.01% 259
2020
Q3 		$709K Sell
10,025
-49,995
-83% -$3.49M 0.06% 169
2020
Q2 		$3.85M Buy
60,020
+59,320
+8,474% +$3.25M 0.36% 58
2020
Q1 		$21K Buy
+700
New +$16.1K ﹤0.01% 355

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Prime Capital Investment Advisors's MRNA Position: Q2 2026 in Review

Prime Capital Investment Advisors increased its Moderna (MRNA) stake by 7.5% in Q2 2026, buying an estimated $17.9K and bringing the position to 4,985 shares worth $349K. The position accounts for ﹤0.01% of the portfolio, ranked #810.

Prime Capital Investment Advisors first reported a position in MRNA in Q1 2020 and has held it in 20 quarters since. The position peaked at $4.92M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Prime Capital Investment Advisors held 4,985 shares of Moderna worth $349K as of Q2 2026.
  • Prime Capital Investment Advisors bought 346 Moderna shares in Q2 2026, an estimated $17.9K.
  • Moderna made up ﹤0.01% of Prime Capital Investment Advisors's portfolio in Q2 2026, its #810 holding.
  • Prime Capital Investment Advisors first reported a position in Moderna in Q1 2020 and has held it in 20 quarters since.
  • Prime Capital Investment Advisors's Moderna position peaked at $4.92M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.